CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIQUID	ASSAY/	*USP42–NF37*	5741	31-May-2019	1-Jun-2019	*NA*	*NA*	In the variable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLUCOSE	*Reducing Sugars*							definition list in *Analysis*: Change C_U = concentration of dextrose equivalent to: C_U = concentration of Liquid Glucose
ROSUVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official April 01, 2019)*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Medium*: Change (dissolve 63.0 of citric acid to: (dissolve 63.0 g of citric acid
DACTINOMYCIN	IDENTIFICATION/*A. Ultraviolet Absorption <197U>/ Acceptance criteria*	*USP42–NF37*	1203	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Absorptivity*: Change The absorptivity of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*. to: The absorptivity,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								calculated on the dried basis, of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*.
DOXORUBICIN HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the fourth equation in *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
EPRINOMECTIN	IMPURITIES/*Organic Impuri*	*USP42–NF37*	1627	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Total unknown impurities*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ties/Acceptance criteria							NMT 1.0 to: NMT 1.0%
SUMATRIPTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4139	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethane sulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethane

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide. to: Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethane

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Sample preparation* and *Analysis*: Change peptone water to: *Peptone diluent*
ARTICLES OF BOTANICAL ORIGIN	TEST FOR A FL ATO XINS/*Method I*	*USP42–NF37*	6701	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Aflatoxin standard solution*: Change ? = molecular absorptivity to: ? = molar absorptivity AND in paragraph 2 of *Aflatoxin standard solution*: Change transfer an

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurate volume of each aflatoxin standard stock solution to: transfer an accurate volume of each aflatoxin stock solution
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	897	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride. $C_{23}H_{29}ClN_2O_3 \cdot 2HCl$ 489.86 to: (*RS*)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cetic acid ethyl ester oxalate. $C_{23}H_{29}ClN_2O_3 \cdot C_2H_2O_4$ 506.98
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the *Standard solution* (mg/mL)
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Test 3*/*Procedure*: Change 1 N sodium hydroxide VS.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 0.1 N hydrochloric acid VS.
MILRINONE	ASSAY/ *Procedure*	*USP42–NF37*	2922	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer*: Change 72.44 g of sodium tetraborate to: 72.44 g of sodium tetraborate, anhydrous
TILETAMINE HYDROCHLORIDE	*Identification/B. Ultraviolet Absorption <197U>*	*USP42–NF37*	4347	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Solution*: Change 0.3 mg per mL. to: 0.03 mg per mL.
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.01 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular*	*USP42–NF37*	857	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Weight Impurities							r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
PHENYLBUTAZONE INJECTION	*Assay*	*USP42–NF37*	3487	31-May-2019	1-Jun-2019	*NA*	*NA*	Change 350(C/V)(R_U/R_S) to: 714.3(C/V)(R_U/R

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIDANOSINE	IM PUR ITIES/*Related Compounds*	*USP42–NF37*	1336	31-May-2019	1-Jun-2019	*NA*	*NA*	In *System suitability solution*: Change 0.5 mg/mL of of didanosine from USP Didanosine System Suitability Mixture RS in *Diluent* to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in *Diluent*
DRONEDARONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1519	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Tolerances*/*30 min*: Change 20.0%–60.0% (*Q*) of the labeled amount of dronedarone free base to: 20.0%–60.0% of the labeled

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								amount of dronedarone free base
GUANABENZ ACETATE	IM PURITIES/*Limit of 2,6-Dichlorobenzaldehyde/Chromatographic system*	*USP42–NF37*	2129	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Column*: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm;
SUMATRIPTAN SUCCINATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4145	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide. to: Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylami

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								no-*N* -o xid e)ethyl]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide.
BACILLUS COAGULANS CAPSULES	ASSAY/ *Enumeration*	*USP42–NF37*	4749	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
SALMETEROL INHALATION POWDER	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In Row 8 of Column 1 of *Table 3*: Change Hyrdoxynaphthoic acid to: Hydroxynaphthoic acid
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1068	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E*,*Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (*E*,*Z*)-2-[4-(1,2-Diphenylvinyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride. Also known as (*E*,*Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride.
DOXORUBICIN HYDROCHLORIDE	ASSAY/ *Procedure*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DULOXETINE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	RS (µg/mg) In footnote a: Change This is a process impurity that is included in *Table 1* for identification purposes only. to: This is a process impurity that is included for identification purposes only.
PIPERAZINE PHOSPHATE	*Assay*	*USP42–NF37*	3549	31-May-2019	1-Jun-2019	*NA*	*NA*	Change Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of $C_4H_{10}N_2 \cdot 2HCl$. to: Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_4H_{10}N_2 \cdot H_3PO_4$.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
NEPHELOMETRY AND TURBIDIMETRY	5. FORMAZIN TURBIDITY STANDARDS	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 1: Change *IUPAC Compendium of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chemical Technology, to: *IUPAC Compendium of Chemical Terminology,*
FELODIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	1787	26-Apr-2019	1-May-2019	*NA*	*NA*	In the second variable definition list in *Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point, *i* to: V_S = volume of the *Sample solution* withdrawn at each time point, *i* (mL)
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 3 of *Table 3*: Change Levalbuterol — — — to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Levalbuterol 1.0 — —
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio of thalidomide to phenacetin is not more than 1.0%.
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6104	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Ferric Nitrate*: Change [10421-48-4]. to: [7782-61-8].
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-	PERFORMANCE TESTS/ *Dissolution*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RELEASE TABLETS	*<711>*							*Release <724>, Figure 4c*) to: (see *Drug Release <724>, Figure 5c*)
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 2 of Column 3 of *Table 4*: Change $0.014^{?}/0.028_{?2S}$ *(USP41)* to: 0.014 AND In Row 3 of Column 3 of *Table 4*: Change 0.014 to: 0.014/0.028 AND In *Chromatographic system*/*Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								e—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) for NLT 20 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2518	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Morphine Related Compound B RS: Change 2,2'-Bimorphine. $C_{34}H_{36}N_2O_6$ 568.66 to: 2,2'-Bimorphine trihydrate. $C_{34}H_{36}N_2O_6 \cdot 3H_2O$ 622.72
INOSITOL	IM PURITIES/*Limit of Lead*	*USP42–NF37*	5776	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Standard lead solution*: Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	10. ALLIGATION ALTERNATE AND ALGEBRA METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHARMACEUTICAL INGREDIENT	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	A comparison solution prepared on the basis of 100 µL of the *Standard lead solution* per g of substance being tested contains the equivalent of 1 part of lead per million parts of substance being tested. In *10.2 Algebra Method*/*10.2.1 Calculating by using the algebra method*/*Examples—Algebra method*: In example *2*, in equations 1, 2, 3, and 4 in all instances: Change C_s to: Q_s AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In example 2, in equation 5: Change C_w to: Q_w
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	410	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Atorvastatin Related Compound A RS: Change Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyhepta

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								noate (1:2); Also known as Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
IMIPRAMINE PAMOATE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A* and *Solution B* and *Diluent*: Change *Chromatographic acetonitrile* to: Acetonitrile
LEVALBUTEROL INHALATION SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol. $C_{13}H_{19}NO_3$ 237.29 [NOTE: This Reference Standard is available as the benzesulfonic acid salt.] to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{2}SO_{4}$ 572.67

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>/Test 1/Instrumental conditions*	*USP42–NF37*	4409	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Cell*: Change 5 cm to: 5 mm
NEPHELOMETRY AND TURBIDIMETRY	4. INSTRUMENTATION	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 2: Change silicone diodes to: silicon diodes
CLONIDINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/*Drug Release <724>/Test 1*	*USP42–NF37*	1084	26-Apr-2019	1-May-2019	*NA*	*NA*	*Apparatus 7*: Change (see *Figure 4a*). to: (see *Figure 5a*).
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Limit of S-Albuterol*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Mobile phase*: Change ?*Acetonitrile*, *methanol*, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.? (USP 1-May-2019) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.
SODIUM BICARBONATE COMPOUNDED INJECTION	ASSAY/ *Procedure for Sodium Bicarbonate*	*USP42–NF37*	4023	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change Result = [(V_S ? V_B) x N_A x F] x 100 to: Result = [(V_S ? V_B) x N_A x F x 100]/W AND Change F = equivalency factor, 84.01 mg/mL to: F = equivalency factor, 84.01 mg/mEq W = sample weight (mg)
REAGENTS AND REFERENCE	REAGENT SPECIFICATIONS	*USP42–NF37*	6079	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Beef Extract/ Microbial*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLES								*Content*: Change MT to: NMT
PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	19. MEAN KINETIC TEMPERATURE/*19.2 MKT Equation*	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In the variable definition list: Change T_n = value for the total number of storage temperatures recorded during the observation period temperature recorded during the nth time period, e.g., *n*th week to: T_n = value for the temperature recorded during the *n*th time period, e.g., *n*th week
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZI	ASSAY/*Procedure/Chromatographi*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Column*: Change 4.6-mm × 15-cm; 5-µm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DE TABLETS	*c system*							packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* $^{?}(90:10)_{?}$ (ERR 1-Mar-2019) for about 30 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7
IMIPRAMINE PAMOATE CAPSULES	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A*: Change *Chromatographic acetonitrile* to: Acetonitrile AND In *Solution B*: Change *chromatographic acetonitrile* to: acetonitrile

Pagination

- First page « First

- Previous page ‹ Previous
- …
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- …
- Next page Next ›
- Last page Last »